| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0002-9343(89)80148-2 |
| P698 | PubMed publication ID | 2672807 |
| P50 | author | Gordon Murray | Q42883581 |
| P2093 | author name string | M A Creager | |
| D L Clement | |||
| J A Dormandy | |||
| S L Nielsen | |||
| J D Coffman | |||
| R J McKendry | |||
| M M Janssens | |||
| P2860 | cites work | The 1982 revised criteria for the classification of systemic lupus erythematosus | Q29547225 |
| Double-blind, placebo-controlled study of prazosin in Raynaud's phenomenon | Q36476969 | ||
| Prazosin treatment of primary Raynaud's phenomenon | Q39342920 | ||
| Treatment of raynaud's phenomenon with ketanserin, a selective antagonist of the serotonin2 (5-HT2) receptor | Q39343520 | ||
| Serotonin as a neurotransmitter in cerebral arteries | Q48896740 | ||
| Preliminary criteria for the classification of systemic sclerosis (scleroderma) | Q54165663 | ||
| Nifedipine in the treatment of Raynaud's phenomenon. Evidence for inhibition of platelet activation | Q67281810 | ||
| Prevention of atherosclerotic complications: controlled trial of ketanserin. Prevention of Atherosclerotic Complications with Ketanserin Trial Group | Q69186555 | ||
| Controlled Double-Blind Trial of Nifedipine in the Treatment of Raynaud's Phenomenon | Q70247572 | ||
| Total and nutritional blood flow in the finger | Q70338251 | ||
| Controlled trial of nifedipine in the treatment of Raynaud's phenomenon | Q72540090 | ||
| Ketanserin (5 HT2-antagonist) in secondary Raynaud's phenomenon | Q72751175 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 264-268 | |
| P577 | publication date | 1989-09-01 | |
| P1433 | published in | American Journal of Medicine | Q2842959 |
| P1476 | title | International study of ketanserin in Raynaud's phenomenon | |
| P478 | volume | 87 |
| Q40805933 | A physician's approach to vasospasm |
| Q41220227 | Cardiac involvement in scleroderma |
| Q34357834 | Digital blood flow and 5-hydroxytryptamine receptor blockade after ketanserin in patients with Raynaud's phenomenon |
| Q34212927 | Drug treatment of scleroderma |
| Q48547759 | Effects of sarpogrelate hydrochloride on skin ulcers and quality of life in patients with systemic sclerosis. |
| Q33908127 | Ketanserin for Raynaud's phenomenon in progressive systemic sclerosis |
| Q33159129 | Ketanserin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in hypertension and peripheral vascular disease |
| Q24202210 | Oral vasodilators for primary Raynaud's phenomenon |
| Q24242978 | Oral vasodilators for primary Raynaud's phenomenon |
| Q38031566 | Pathogenesis and treatment of Raynaud's phenomenon |
| Q39460894 | Pharmacotherapy of Raynaud's phenomenon |
| Q36890481 | Physiopathology of Raynaud phenomenon: current data |
| Q71788213 | Raynaud's phenomenon |
| Q33631731 | Raynaud's phenomenon: its relevance to scleroderma |
| Q40476947 | Serotonin and Serotonin Antagonism in Cardiovascular and Non‐Cardiovascular Disease |
| Q35306379 | Serotoninergic status in patients with hereditary vascular retinopathy syndrome |
| Q37344793 | Vascular disease in scleroderma |
Search more.